Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549972
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Predictive Role of Early Blood KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of Acute Ischemic Stroke
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 KLK10 soluble triggering receptor expressed on myeloid cells 2 sTREM2 and glial fibrillary acidic protein GFAP in the plasma of patients with first-ever anterior circulation acute ischemic stroke AIS It will analyze the correlation between these molecules and the severity of neurological deficits infarct volume brain edema hemorrhagic transformation progressive stroke and clinical outcomes at three months The goal is to assess the predictive value of these molecules for AIS prognosis guiding early treatment and new molecular targets for prevention and treatment
Detailed Description:
1 Informed Consent and Recruitment Participants will be recruited based on inclusion and exclusion criteria
2 divided two groups the case groupischemic stroke group and the control grouphealthy individuals
3 First surveyAt the time of admission baseline Assessment- Survey on gender age medical history smoking drinking habits and current medication NIHSS score at admission measurement of plasma levels of KLK10 sTREM2 and GFAP a collection of blood glucose creatinine high-sensitivity C-reactive protein blood cell analysis report and brain MRI or CT imaging reports
4 Second survey24 hours after onset NIHSS Score and Plasma Levels of KLK10 sTREM2 and GFAP Detection
5 Third surveyWithin 7 days of onset Obtain brain CT or MRI reports to extract information on infarct volume brain edema and hemorrhagic transformation perform NIHSS scoring to assess the occurrence of progressive stroke
6 Forth survey 3 months after onset Final Assessmentif Good Functional Outcome or MortalityRecord the Modified Rankin Scale mRS score at 3 months after stroke
2 divided two groups the case groupischemic stroke group and the control grouphealthy individuals
3 First surveyAt the time of admission baseline Assessment- Survey on gender age medical history smoking drinking habits and current medication NIHSS score at admission measurement of plasma levels of KLK10 sTREM2 and GFAP a collection of blood glucose creatinine high-sensitivity C-reactive protein blood cell analysis report and brain MRI or CT imaging reports
4 Second survey24 hours after onset NIHSS Score and Plasma Levels of KLK10 sTREM2 and GFAP Detection
5 Third surveyWithin 7 days of onset Obtain brain CT or MRI reports to extract information on infarct volume brain edema and hemorrhagic transformation perform NIHSS scoring to assess the occurrence of progressive stroke
6 Forth survey 3 months after onset Final Assessmentif Good Functional Outcome or MortalityRecord the Modified Rankin Scale mRS score at 3 months after stroke
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None